FDA OKs Eltrombopag (Promacta) for Severe Aplastic AnemiaFDA OKs Eltrombopag (Promacta) for Severe Aplastic Anemia

Eltrombopag is indicated for patients with severe aplastic anemia who fail to respond adequately to immunosuppressive therapy. FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news